糖皮质激素诱导骨质疏松的机制和治疗进展

被引：27

作者：

王保平 ^{[1
]}

贾红蔚 ^{[1
]}

郑纺 ^{[2
]}

朱梅 ^{[1
]}

机构：

[1] 天津医科大学总医院内分泌代谢科

[2] 天津中医药大学中西医结合学院

来源：

实用医学杂志 | 2018年 / 34卷 / 14期

基金：

天津市自然科学基金;

关键词：

糖皮质激素诱导的骨质疏松; 机制; 治疗;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

糖皮质激素可通过多种机制,包括抑制成骨细胞的增殖和分化;增加成熟成骨细胞和骨细胞的凋亡;延长破骨细胞的寿命和活性等引起骨质疏松。虽然双膦酸盐可降低椎体骨折风险,但其主要作用是抑制骨吸收,长期应用会导致骨微损伤蓄积。研究发现狄诺塞麦,特立帕肽,VitK2等药物可改善糖皮质激素治疗引起的骨形成下降,将为临床治疗糖皮质激素诱导的骨质疏松提供新的选择。

引用

页码：2290 / 2292

页数：3

共 14 条

[1]

鹿瓜多肽联合唑来膦酸治疗糖皮质激素性骨质疏松症的远期疗效及对骨密度的影响 [J].

鲁宏 ;

晏宏伟 .

中国全科医学, 2017, 20(S1) (S1) :224-226

[2]

糖皮质激素诱导的骨质疏松诊治的专家共识.[J]..中华风湿病学杂志.2013, 06

[3]

Parathyroid Hormone (PTH) Induces Autophagy to Protect Osteocyte Cell Survival from Dexamethasone Damage..[J].Zhu Liang;Chen Jifei;Zhang Jing;Guo Changan;Fan Wenshuai;Wang YiMing;Yan Zuoqin.Medical science monitor : international medical journal of experimental and clinical research.2017,

[4]

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates [J].

Seno, Takahiro ;

Yamamoto, Aihiro ;

Kukida, Yuji ;

Hirano, Aiko ;

Kida, Takashi ;

Nakabayashi, Amane ;

Fujioka, Kazuki ;

Nagahara, Hidetake ;

Fujii, Wataru ;

Murakami, Ken ;

Oda, Ryo ;

Fujiwara, Hiroyoshi ;

Kohno, Masataka ;

Kawahito, Yutaka .

SPRINGERPLUS, 2016, 5

[5]

Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis invivo and invitro [J].

Chen, Zhiguang ;

Xue, Jinqi ;

Shen, Tao ;

Ba, Gen ;

Yu, Dongdong ;

Fu, Qin .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2016, 43 (02) :268-276

[6]

MicroRNA-29a mitigates glucocorticoid induction of bone loss and fatty marrow by rescuing Runx2 acetylation.[J].Jih-Yang Ko;Pei-Chin Chuang;Huei-Jin Ke;Yu-Shan Chen;Yi-Chih Sun;Feng-Sheng Wang.Bone.2015,

[7]

Management of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk [J].

Kenanidis, Eustathios ;

Potoupnis, Michael E. ;

Kakoulidis, Panagiotis ;

Leonidou, Andreas ;

Sakellariou, Grigorios T. ;

Sayegh, Fares E. ;

Tsiridis, Eleftherios .

EXPERT OPINION ON DRUG SAFETY, 2015, 14 (07) :1035-1053

[8]

Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: A 12-month randomized controlled trial.[J].Chi Chiu Mok;Ling Yin Ho;Kwok Man Ma.Bone.2015,

[9]

Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis [J].